Women with a diabetic sibling are at an increased risk of developing gestational diabetes much more than having one or even two diabetic parents, according to a new study in the American Journal of Obstetrics and Gynecology, Reuters reports. The study's authors said the results seem to suggest that gestational diabetes follows a different inheritance path than Type 2 diabetes, which is typically associated with being overweight. The study found that having two parents with diabetes increased a woman's likelihood of having diabetes eightfold but only doubled the likelihood of gestational diabetes. When a woman has a diabetic sibling, there was a sevenfold increase in the risk of gestational diabetes but only a slightly elevated risk of Type 2 diabetes. The results were based on a study of 4, 566 mothers who participated in the National Health and Nutritional Examination Survey. "Sibling-only history may be a greater risk factor than previously documented, " study author Catherine Kim of the University of Michigan Medical School and colleagues wrote.
Type 2 Diabetes Is Still A Silent Killer - Most People Diagnosed Did Not Recognise Early Symptoms, UK
Just over half (56 per cent) of people diagnosed with Type 2 diabetes last year did not even suspect they could have the condition, as they failed to identify its early symptoms, says a new report by Diabetes UK. Late diagnosis of Type 2 diabetes leaves people at risk of developing the serious complications of the condition, including stroke, heart disease, blindness, kidney disease and amputation - half of the people with the condition already show signs of complications by the time they are diagnosed. Most only diagnosed 'by accident' In addition, the majority of people were diagnosed with the condition 'by accident' while undergoing routine medical tests or while being treated for other conditions or medical issues: only 16 per cent of people were diagnosed after they proactively asked for a diabetes test. Up to half a million unaware of their diabetes Diabetes UK estimates that there are up to 500, 000 people in the UK who have diabetes but are not aware of it. Be aware of the risk and ask for a test "We need to make sure that people are aware of the risk factors and symptoms of Type 2 diabetes and we need to encourage them to ask for a diabetes test if they are at risk of developing the condition, " said Douglas Smallwood, Chief Executive of Diabetes UK.
In two major studies published in Nature Genetics today, researchers use biological understanding to dissect the genetics of diabetes. An international team comprising researchers from more than 100 institutions analysed vast suites of genetic data from more than 100, 000 people of European descent to uncover the associations. In the first study, the team identified ten novel genetic markers for biological traits underlying type 2 diabetes. In a companion paper the same consortium identified three new variants that are associated with raised levels of glucose seen in a common test for type 2 diabetes. The results help to unravel the complex biological story of type 2 diabetes: as well as revealing five new associations that influence directly the risk of diabetes, this research will drive studies to understand the biology of disease and to search for treatments to alleviate the burden caused by the disease. The team are working to understand the normal metabolism of glucose as well as diseases of glucose metabolism, such as diabetes.
Diabetes UK's Measure Up Roadshow 2009 has encouraged more than 77, 000 people in the UK to measure their waists and find out if they are at risk of developing Type 2 diabetes. The Roadshow has handed out at least 77, 082 leaflets and risk assessed 5, 550 people, out of which 1, 929 have been referred to their GP to find out if they have Type 2 diabetes. Risk factors for Type 2 diabetes The Measure Up Roadshow, which kicked off in June 2009, toured the country until the end of December in a bid to help people find out more about Type 2 diabetes and its risk factors. These include: - having a large waist (37 inches or more for men, except those of South Asian origin who are at risk at 35 inches or more, and 31.5 inches or more for all women) - being over 40 years old or over 25 if you are of Black or South Asian origin - being of Black or South Asian origin - having a family history of the condition. Phillip Schofield asks you to Measure Up The campaign was backed by TV presenter Phillip Schofield.
Diabetes UK is calling on people with Type 2 diabetes who self-monitor their blood glucose levels to complete a short online survey. The survey, which you can fill in here, will help inform ongoing work on self-monitoring blood glucose levels that will directly improve the lives of people with diabetes. "Knowing the level of glucose in your blood is useful for when people try to control their diabetes, " said Caroline Butler, Care Advisor at Diabetes UK. "It can help to maintain day-to-day control, detect hypoglycaemia and assess control during any illness. "It also provides information that can help reduce the risk of developing long-term complications associated with diabetes such as heart disease, stroke and blindness." Source Diabetes UK
An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes. The results of two studies, conducted by the Meta-Analyses of Glucose and Insulin Related Traits Consortium (MAGIC), provide important clues about the role of beta cells in the development of type 2 diabetes. The studies, funded in part by the National Institutes of Health, appear online Jan. 17, 2010, in Nature Genetics. "The findings from these ambitious, large-scale studies represent an enormous achievement in international cooperation involving hundreds of researchers and many thousands of individuals who contributed genetic samples for the study. The results give us exciting new directions for future research in the biology of type 2 diabetes, which poses a major and growing public health problem worldwide, " said NIH Director Francis S.
The discovery of an inflammatory mediator key to the blinding effects of diabetic retinopathy is pointing toward a potential new treatment, Medical College of Georgia researchers said. Interleukin-6, known to contribute to the debilitating joint inflammation of rheumatoid arthritis, also helps ignite inflammation of the retina, a first step in a disease that is the leading cause of blindness is working-age adults, MCG researchers reported online in Investigative Ophthalmology & Visual Science. The finding has the scientists looking at whether an interleukin-6 antibody, which is showing success in treating rheumatoid arthritis, can halt inflammation in mice with diabetic retinopathy. "We expect that this neutralizing antibody can be used to treat diabetic retinopathy in the future, " said Dr. Wenbo Zhang, assistant research scientist in MCG's Vascular Biology Center. Drs. Zhang and Modesto Rojas, senior postdoctoral fellow, are co-first authors on the paper. Angiotensin II, a powerful constrictor of blood vessels, is typically associated with the kidneys where it plays a vital role in regulating blood pressure.
Many healthcare professionals are failing to advise people with medical conditions that could affect their ability to drive whether they should get behind the wheel, according to research from the University of Warwick. Researchers from the University's Warwick Medical School have found many healthcare professionals are failing to tell patients with certain conditions such as diabetes or visual impairment if they are not fit to drive. In a study undertaken for the Department for Transport, the research team explored the knowledge and attitudes of healthcare professionals towards advising patients about their fitness to drive. The researchers recruited 1519 health professionals, 358 patients and 55 medical school personnel to the study. The research team, led by Dr Carol Hawley, Principal Research Fellow at Warwick Medical School, found doctors in training received little tuition on medical aspects of fitness to drive. They also found that although most healthcare professionals were aware of the Driving and Vehicle Licensing Agency (DVLA) guidelines stipulating fitness to drive, many were unable to reliably distinguish between medically unfit drivers, borderline drivers and fit drivers.
A new evidence review suggests that using a pump to deliver insulin continuously instead of taking three or more daily injections might result in better control of blood sugar for people with type 1 diabetes. "The findings of this review tell us that both continuous subcutaneous insulin infusion and multiple injections correct blood glucose levels. However, [continuous infusion] may be better for reducing harmful fluctuations in blood glucose, " said lead author Marie Misso, Ph.D. Type 1 diabetes which used to be known as juvenile diabetes results when the pancreas is not able to secrete enough insulin, causing the levels of glucose (or sugar) in the blood to rise. Chronically high blood glucose can lead to heart attacks, circulation problems and blindness. Low levels can lead to unconsciousness and even death. Type 1 diabetes is one of the most common chronic diseases of childhood. Most people with the condition control their glucose by injecting themselves with insulin three or more times per day.
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces the absence of a safety risk due to pharmacokinetic drug-drug interaction when GFT505 is co-administered with a statin (GFT505-1095 clinical study). These results prepare the launch of Phase IIb and Phase III trials in patients already treated with a statin (on-top of statin trials). Furthermore, GENFIT is now evaluating the opportunity to develop a combination therapy associating GFT505 with a generic statin in the same pill. Certain fibrates are associated with an increased risk of serious muscular side-effects when they are co-administered with a statin. Indeed, these drugs significantly increase the plasma concentration of certain statins (including simvastatin) and/or their active metabolites. This pharmacokinetic drug-drug interaction increases the risk of muscular side-effects associated with hypolipidemic agents.